Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

Ischemic Stroke Clinical Trial

Official title:

A Randomized, Double-blind, Placebo Controlled Evaluation, Multicenter Clinical Study of Tongxinluo Capsule in Ischemic Stroke Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01919671
• Other study ID #: yl-yxb09-lcsyfa-201301
• Status: Completed
• Phase: Phase 4
• First received: August 7, 2013
• Last updated: January 3, 2017
• Start date: March 2014
• Est. completion date: November 2016

Study information

• Verified date: January 2017
• Source: Ministry of Science and Technology of the People´s Republic of China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effects in improving life self-care ability of stroke patients after taking Tongxinluo Capsule(within 72 hours after onset) versus Placebos for 90 days.

Description:

The study is a randomized, double-blind, placebo controlled, multi-center trial. We aim to enroll a total of 1968 individuals(984 cases in each group) with acute ischemic stroke less than 72 hours after onset. Participants will be randomized into Tongxinluo capsule treatment group with the capsule administration of 4 granules tid. for 90 days, while the patients in the control group receive placebo capsule. NIH Stroke Score of the subjects is 4-22 at randomization. Evaluations of efficacy and safety will be taken at baseline, 7 days, discharge date and 90 days. Neuroimaging [magnetic resonance imaging (MRI) scans] will be obtained at baseline and 90 days after therapy. The primary efficacy endpoint is the proportion of Modified Rankin Scale (mRS) ≤1 at 90 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2007
• Est. completion date: November 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Ischemic stoke within 72 after onset, confirmed by MRI or CT.

• Age 35-75 years, inclusive.

• Patients with the first attack or patients with stroke history(modified Rankin Scale score 0-1).

• Clear signs of localization of nervous system, NIHSS score 4 to 22.

• Patient or proxy has signed informed consent.

Exclusion Criteria:

• Hemorrhage diseases according to head CT or MRI, such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, haemorrhage after cerebral infarction.

• Transient Ischemic Attack (TIA).

• Severe disturbance of consciousness: 1a of NIHSS score>1 point; Difficulty in swallowing, unable to take oral capsules; any of 5a, 5b, 6a, 6b of NIHSS score>2 point.

• Convinced of stroke caused by brain tumor, brain trauma, hemopathy, etc.

• Hemorrhagic tendency patients.

• Patients with endovascular treatment after the onset of stroke.

• Patients with dementia, severe Parkinson's disease, mental disorders, limb dysfunction caused by other diseases or other conditions that may affect the therapeutic efficacy.

• Uncontrolled hypertension (=200 mmHg systolic or =110 mmHg diastolic) or hypotension (=90 mmHg systolic or =60mmHg diastolic); severe hyperglycemia(blood glucose =400 mg/dl) or hypoglycemia( blood glucose=50 mg/dl).

• Severe hepatic insufficiency defined as transaminase values > 2x upper limit of normal; severe renal insufficiency defined as values serum creatinine> 1.5x upper limit of normal; cardiac dysfunction or other serious systemic disease with life expectancy =3 months.

• Patients with concurrent malignancy or ongoing anti-tumor therapy.

• Patients with history of being allergic to the trial medicine.

• Pregnancy, breastfeeding or potential pregnancy.

• Within three months or currently participating in another investigational study.

• Any other condition that in the opinion of the investigator should preclude study participation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• Tongxinluo capsule
for 90 days
• placebo capsule
for 90 days

Locations

Country	Name	City	State
China	Beijing TianTan Hospital,Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
yongjun wang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	MR indicated symptomatic or non-symptomatic cerebral infarction emerging	Compared with baseline MRI, re-examination of MRI shows new infarct diagnosed by DWI or FLARI (including new infarct and enlargement of infarct size) in areas other than the original infarct in DWI and FLAIR-sequence.	90 days	Yes
Primary	Proportion of patients with Modified Rankin Scale (mRS) less than or equal to 1 at 90 days.		90 days	No
Secondary	Proportion of patients with National Institutes of Health Stroke Score (NIHSS) reaching 0-1 or reduction 4 points .		Baseline, 7days, discharge date, 90 days	No
Secondary	Proportion of patients with Bathel Index(BI)score more than 85.		Baseline, 7days, discharge date, 90 days	No
Secondary	Continuous changes of Modified Rankin Scale score.		Baseline, 7days, discharge date, 90 days	No
Secondary	Incidence of ischemic cerebrovascular disease (ischemic stroke/TIA/ new ischemic lesion in MRI Images.		90 days	Yes
Secondary	Incidence of new combination clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death).		90 days	Yes